Leading Minds **Network**™
Insight Report

From Temperature Control to Network Orchestration

What Pharma, Life Science, Healthcare, and Logistics Leaders Revealed About the Future of Cold Chain



November 2026



2 **Executive Summary**
3 **Key Findings**
4 **Seminar Response Snapshots**
5 **Analysis: What the Seminar Responses Reveal**
7 **Executive Implications**
7 **Conclusion**
8 **Source Appendix**
9 **About LMN**

"The competitive frontier is no longer temperature control, it's real-time orchestration of compliant, visible, and scalable partner networks."

Executive Summary

The Leading Minds Network™ seminar responses in San Diego revealed a clear executive-level shift: the biologics cold chain is no longer viewed primarily as a temperature-control problem. Leaders increasingly see it as a network-orchestration challenge shaped by infrastructure, capacity, data visibility, partner coordination, regulatory change, and cost-to-scale. This perspective closely matches external guidance and market analysis from sources including the European Commission, WHO, IATA, FDA, EMA, McKinsey, IQVIA, DHL, World Courier, and others.

- Seminar attendees repeatedly described the cold chain as complex, demanding, unpredictable, and temperamental, language that aligns with regulatory and market sources describing increasingly complex, multi-party distribution networks.
- The most frequently cited readiness gaps for biologics at scale were capacity, infrastructure, data management, risk assessment, and visibility.
- When shipments go off plan, attendees said the biggest challenge is coordinating across partners, not simply detecting the issue or identifying who owns the response.
- Change control emerged as the hardest regulatory or quality requirement to operationalize, pointing to a deeper challenge: maintaining validated control while routes, partners, modalities, and delivery models continue to evolve.
- For direct-to-patient biologic delivery, attendees identified location, infrastructure, and cost as the leading barriers, consistent with regulatory and operational sources showing that DTP delivery is promising but highly dependent on local capability.
- For ultra-cold and cryogenic transport, cost and scalability ranked as the leading concern, signaling that leaders are now focused not only on technical feasibility but on sustainable operating economics.

Key Findings

1. Cold chains have become a systems problem, not a storage problem.

Attendee feedback reflects an industry reality documented in GDP, WHO, and IATA guidance: modern pharmaceutical distribution spans many players, handoffs, controls, and outsourced activities.

2. Readiness for biologics at scale requires more than capacity.

Capacity and infrastructure matter, but the seminar responses also emphasized data management, risk assessment, and visibility. This indicates that leaders are prioritizing operating intelligence, not just physical assets.

3. The biggest shipment recovery gap is orchestration.

The top selected struggle when a shipment goes off plan was coordinating across partners. This suggests that cold-chain maturity increasingly depends on how quickly a network can align, decide, and act when conditions change.

4. Change control is a hidden executive risk.

Attendees ranked change control as the hardest regulatory or quality requirement to apply. This is notable because it points to the operational strain of maintaining compliant, validated networks while logistics partners, lanes, packaging, and delivery channels change.

5. Direct-to-patient delivery is advancing, but unevenly.

FDA and EMA guidance supports decentralized trial elements and patient-convenient models, but attendees' concerns around location, infrastructure, and cost highlight practical barriers to scaling DTP biologic delivery.

6. Ultra-cold and cryogenic transport is now an economic question.

Cost and scalability outranked packaging performance and duration as the top concern. The implication: technical validity is necessary, but repeatable economics will determine broader adoption.

7. The next maturity phase is decision support.

Action items from attendees clustered around collaboration, data ownership, data sharing, visibility, and AI. This points toward a future where organizations compete on how well they convert cold-chain signals into coordinated action.



Seminar Response Snapshots

This report compares qualitative and ranked responses from the Leading Minds Network seminar in San Diego, CA with external research and regulatory guidance related to biologics cold chain, radiopharmaceutical logistics, direct-to-patient delivery, and ultra-cold/cryogenic transport.

The seminar source materials reviewed were the uploaded response workbook and summary PDF for the 2026 San Diego session. External sources were used to identify documented market, regulatory, and operational trends.

Readiness gap for biologics at scale	**Seminar Signal** Capacity, infrastructure, data management, risk assessment, and visibility were the leading themes.
Off-plan shipment response	**Seminar Signal** Coordinating across partners was the top struggle, followed by detecting issues fast enough.
Radiopharmaceutical logistics risk	**Seminar Signal** Transportation speed and routing ranked as the greatest risk of failure.
Regulatory/ quality difficulty	**Seminar Signal** Change control ranked highest, followed by 3PL/partner oversight and direct-to-patient compliance.
Direct-to-patient biologic delivery barrier	**Seminar Signal** Location, infrastructure, and cost were the most common barriers.
Ultra-cold/ cryogenic concern	**Seminar Signal** Cost and scalability ranked first, followed by packaging performance and duration.
Action items	**Seminar Signal** Collaboration, innovation, data sharing/ownership, visibility, AI, and risk assessment were common takeaways.





Analysis: What the Seminar Responses Reveal

1. Complexity is now the baseline operating condition

Attendees consistently described the biologics cold chain as complex, unpredictable, temperamental, and demanding. Those descriptors mirror the formal language of modern GDP and WHO guidance, which treat pharmaceutical distribution as a multi-party system requiring qualification, documentation, monitoring, temperature control, supplier oversight, outsourced-activity management, and defined transport controls.

This alignment indicates that the seminar audience was not merely expressing frustration; they were articulating the lived reality of an increasingly complex regulated network. Industry research from IQVIA and Alvarez & Marsal similarly frames cold chain growth as part of a wider shift toward biologics, specialty medicines, advanced therapies, real-time monitoring, and more patient-proximate distribution models.

2. Scaling biologics requires readiness across assets, data, and governance

When asked about readiness gaps for biologics at scale, attendees emphasized capacity and infrastructure, but also data management, risk assessment, and visibility. This is an important distinction. It suggests that organizations recognize physical expansion alone will not solve scale challenges if they lack the data and governance needed to control increasingly distributed networks.

External research supports this interpretation. McKinsey has highlighted capacity pressure and operational visibility gaps in biopharma production, while DHL and other logistics sources describe life sciences supply chains being reshaped by advanced therapies, patient-centric models, resilience needs, and colder temperature requirements.

3. Off-plan shipment response is an orchestration challenge

The clearest operational finding from the seminar was that coordinating across partners is the leading struggle when a cold chain shipment goes off plan. This ranked above issue detection, owner identification, reliable real-time data, and rapid escalation.

That finding is especially meaningful because it highlights the difference between monitoring and orchestration. Real-time data is valuable, but data alone does not resolve a shipment exception. Resolution requires aligned processes, known decision rights, timely escalation, partner cooperation, and the ability to act while product viability, patient need, and compliance risk are all in play.

4. Change control is where dynamic networks meet static compliance expectations

The seminar audience identified change control as the most difficult regulatory or quality requirement to apply. This is a notable finding because change control is often less visible than excursions, packaging, lane validation, or monitoring technology—but it is central to compliant scale. As biologics networks evolve, organizations must manage changes to lanes, partners, packaging, monitoring tools, site requirements, delivery models, and data systems. Each change may require risk assessment, documentation, validation, training, or quality approval. The result is a hidden operational burden: maintaining compliant control while the network is continuously changing.

Cold chain maturity is shifting from “more monitoring” to better cross-partner decision-making.

5. Radiopharmaceuticals compress the margin for error

For radiopharmaceutical logistics, attendees ranked transportation speed and routing as the greatest risk of failure. This aligns with external sources emphasizing short half-lives, stringent regulations, specialized infrastructure, capacity constraints, and time-sensitive distribution requirements.

The practical implication in this sector is straightforward: the operational clock can be the first and most unforgiving constraint. Chain of custody and documentation remain critical, but if route speed and reliability fail, downstream controls may not be enough to preserve clinical or commercial value.

6. Direct-to-patient delivery is attractive, but execution is local

Attendees identified location, infrastructure, and cost as the biggest barriers to wider adoption of direct-to-patient biologic delivery. This matches the broader market: regulatory frameworks increasingly support decentralized or patient-convenient models, but operational success depends on local service coverage, trained personnel, compliant handling, patient availability, delivery coordination, and reimbursement economics.

The finding helps temper overly broad claims about DTP. The model can improve patient access and reduce site burden, but it is not infrastructure neutral. In many cases, geography and service capacity determine feasibility.

7. Ultra-cold and cryogenic transport must prove commercial scalability

For ultra-cold and cryogenic transport, cost and scalability ranked above packaging performance and duration. This suggests that many leaders are no longer asking only whether ultra-cold models can work technically. They are asking whether those models can be run repeatedly, compliantly, and economically at scale.

This is consistent with industry attention to advanced therapies, cryogenic storage, biologic temperature stability, and the economic burden of cold-chain systems. The next wave of maturity will likely depend on better stability knowledge, improved packaging economics, reliable lane performance, and stronger orchestration across handoffs.





Executive Implications

- Build orchestration capability, not just visibility. Organizations should define how exceptions are detected, triaged, escalated, assigned, and resolved across partners before shipments move.
- Treat data governance as a cold chain control. Temperature, location, handoff, and excursion data should be usable for real-time intervention, audit readiness, partner performance review, and continuous improvement.
- Stress-test change control under real operating conditions. Quality systems should be evaluated against the actual rate of network change: new lanes, DTP models, packaging changes, monitoring tools, 3PL changes, and site requirements.
- Separate DTP ambition from DTP readiness. DTP strategies should be assessed by geography, service coverage, patient coordination needs, local regulation, trained support capacity, and total landed cost.
- Model ultra-cold economics early. Cryogenic and ultra-cold models should be evaluated not only for technical performance but also reuse models, packaging dwell time, recovery workflows, lane reliability, and commercial scalability.
- Use AI first where decisions are repetitive, time-sensitive, and data-rich. Examples include weather-risk prediction, lane risk scoring, exception prioritization, vendor comparison, and predictive excursion prevention.

Conclusion

The San Diego seminar responses were highly consistent with external research and regulatory direction. Their value is that they translate market trends into practical operating pressure points: coordination, infrastructure, visibility, change control, DTP feasibility, and ultra-cold scalability.

The overarching conclusion is clear: the future of pharma cold chain will be won by organizations that can orchestrate complex, compliant, multi-partner networks, not merely monitor them.

Source Appendix

1. Alvarez & Marsal. Growth in the Biopharma Cold Chain Market: A Perspective on New Pockets of Value. July 2024.
2. DHL. Specialty Pharma Logistics. DHL.
3. DHL Group. “Advancing Healthcare Delivery: DHL White Paper Identifies Trends, Changes, and Solutions in Life Sciences and Healthcare Supply Chains.” DHL Group, 28 June 2023.
4. European Commission. Guidelines on Good Distribution Practice of Medicinal Products for Human Use.
5. European Medicines Agency. “Facilitating Decentralised Clinical Trials in the EU.” European Medicines Agency, 19 Dec. 2022.
6. Food and Drug Administration. “Conducting Clinical Trials with Decentralized Elements.” U.S. Food and Drug Administration, Sept. 2024.
7. Food and Drug Administration. “Initiative to Benchmark and Profile Monoclonal Antibody and Large Biomolecule Stability.”
8. Global Industry Analysts, Inc. Direct-to-Patient Healthcare Logistics—Global Strategic Business Report. Research and Markets, July 2025.
9. International Air Transport Association. Pharma & Healthcare.
10. International Air Transport Association. Pharmaceutical Logistics: CEIV Pharma Brochure.
11. IQVIA. Pharma’s Frozen Assets: Cold Chain Medicines. IQVIA, 27 Jan. 2023.
12. IQVIA. Tip of the Iceberg: Economic and Environmental Impact of the Vaccine Cold Chain.
13. Leading Minds Network. Leading Minds Seminar San Diego 2026—Response Workbook. 9 June 2026. Microsoft Excel file.
14. Leading Minds Network. Leading Minds Seminar San Diego 2026—Summary PDF. 9 June 2026. PDF file.
15. McGuireWoods. “Radiopharmaceutical Industry Update: Q4/Q1 2024–2025.” McGuireWoods, 7 Apr. 2025.
16. McKinsey & Company. “Human–Machine Harmonization to Upgrade Biopharma Production.” McKinsey & Company, 8 May 2025.
17. McKinsey & Company. “Supply Chains: Still Vulnerable.” McKinsey & Company, 14 Oct. 2024.
18. Rushton, Dave. “Cold Chain Management: GDP Compliance in the Global Pharmaceutical Market.” UK GDP Association, 4 Apr. 2025.
19. World Courier. “EU Picks Up Pace on Home Delivery of Study Drugs.” World Courier, 21 Sept. 2023.
20. World Courier. “Prevent Temperature Excursions in Pharmaceutical Cold Chain.” World Courier, 14 Apr. 2024.
21. World Health Organization. Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products. WHO Technical Report Series, no. 961, Annex 9, 2011.
22. “Increasing Access to Home Specialty Infusions in Rural Health Care.” Infusion Nurses Society, 10 June 2025.



Where Leading Pharma Minds Meet™

- Peer-to-Peer Collaboration
- Global Onsite Seminar Series
- "Temperature Control Tuesdays" Webinar Series
- Member Updates & News
- Leading Industry Experts & Partners
- Free to Join – No Membership Fee

Join our Community
leading-minds-network.com

Powered by ELPRO COLD CHAIN TECHNOLOGIES

Affiliates ASC ccp

About Leading Minds Network

The Leading Minds Network, powered by ELPRO and Cold Chain Technologies is a collaborative learning peer-to-peer community that brings together pharmaceutical, life science, healthcare and logistic industry professionals to benchmark ideas, collaborate and share best practices. In doing so, they work together to fulfill a mission serving the greater good: to provide safe and effective medications and therapies for patients worldwide.

Learn more and join today at: **www.leading-minds-network.com**

All rights reserved. Copyright Leading Minds Network™